| P50 | author | Calvin Yeang | Q56998685 |
| | Joseph L Witztum | Q62567829 |
| | Sotirios Tsimikas | Q80167861 |
| | Amir Ravandi | Q87691607 |
| | Michael Torzewski | Q96192526 |
| P2093 | author name string | Xiaohong Yang | |
| | Laura Twardowski | |
| | Ulrich F W Franke | |
| | Jens Schmid | |
| | Andrea Edel | |
| | Rahul Bhindi | |
| | Stefan Kath | |
| P2860 | cites work | Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. | Q54694067 |
| | Aortic stenosis begets aortic stenosis: between a rock and a hard place? | Q61727656 |
| | Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis | Q71066383 |
| | Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo | Q71089370 |
| | Bone formation and inflammation in cardiac valves | Q73635711 |
| | Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis | Q84067868 |
| | Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve | Q85675771 |
| | Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis | Q26822962 |
| | Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. | Q34353340 |
| | A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma | Q34656639 |
| | Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). | Q35212866 |
| | Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. | Q35836894 |
| | Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans | Q36617508 |
| | Enzymatically Modified Low-Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease | Q36836028 |
| | Genetic associations with valvular calcification and aortic stenosis | Q37154922 |
| | Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). | Q37163064 |
| | Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus | Q37372596 |
| | Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients | Q37899611 |
| | Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study | Q38297438 |
| | Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis | Q38701405 |
| | Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis | Q38839978 |
| | Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). | Q38840197 |
| | 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement | Q39859303 |
| | Calcification of the aortic valve: its progression and grading | Q40643514 |
| | Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis | Q41372923 |
| | LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. | Q43195931 |
| | Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial | Q43202673 |
| | Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis | Q43638006 |
| | Oxidative stress modulates osteoblastic differentiation of vascular and bone cells | Q43702897 |
| | Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization | Q44621087 |
| | Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. | Q45904176 |
| | Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. | Q45944920 |
| | Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. | Q45946808 |
| | Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). | Q46387230 |
| | A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis | Q46535596 |
| | Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). | Q46625599 |
| | Valvular (18)F-Fluoride and (18)F-Fluorodeoxyglucose Uptake Predict Disease Progression and Clinical Outcome in Patients With Aortic Stenosis. | Q52991181 |
| P433 | issue | 3 | |
| P921 | main subject | LPA | Q18028636 |
| P304 | page(s) | 229-240 | |
| P577 | publication date | 2017-06-26 | |
| P1433 | published in | JACC. Basic to Translational Science | Q27727237 |
| P1476 | title | Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis | |
| P478 | volume | 2 | |